Literature DB >> 22897844

Burkitt lymphoma: much more than MYC.

David Dominguez-Sola1, Riccardo Dalla-Favera.   

Abstract

Chromosomal translocations causing deregulated c-MYC expression are detectable in most Burkitt lymphoma cases. However, little is known about the additional lesions necessary for lymphomagenesis. Now, two independent studies, one of which was performed by Sander et al. in this issue of Cancer Cell, identify constitutive PI3K signaling and CyclinD3 mutations as cooperating lesions in both mice and humans. The results have directly actionable therapeutic implications.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22897844     DOI: 10.1016/j.ccr.2012.07.018

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  8 in total

1.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

2.  Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.

Authors:  Julia Richter; Matthias Schlesner; Steve Hoffmann; Markus Kreuz; Ellen Leich; Birgit Burkhardt; Maciej Rosolowski; Ole Ammerpohl; Rabea Wagener; Stephan H Bernhart; Dido Lenze; Monika Szczepanowski; Maren Paulsen; Simone Lipinski; Robert B Russell; Sabine Adam-Klages; Gordana Apic; Alexander Claviez; Dirk Hasenclever; Volker Hovestadt; Nadine Hornig; Jan O Korbel; Dieter Kube; David Langenberger; Chris Lawerenz; Jasmin Lisfeld; Katharina Meyer; Simone Picelli; Jordan Pischimarov; Bernhard Radlwimmer; Tobias Rausch; Marius Rohde; Markus Schilhabel; René Scholtysik; Rainer Spang; Heiko Trautmann; Thorsten Zenz; Arndt Borkhardt; Hans G Drexler; Peter Möller; Roderick A F MacLeod; Christiane Pott; Stefan Schreiber; Lorenz Trümper; Markus Loeffler; Peter F Stadler; Peter Lichter; Roland Eils; Ralf Küppers; Michael Hummel; Wolfram Klapper; Philip Rosenstiel; Andreas Rosenwald; Benedikt Brors; Reiner Siebert
Journal:  Nat Genet       Date:  2012-11-11       Impact factor: 38.330

3.  Correlation between the protein expression of A-kinase anchor protein 95, cyclin D3 and AKT and pathological indicators in lung cancer tissues.

Authors:  Xiuyi Yu; Yangyang Yuan; Xuehong Zhi; Bogang Teng; Xiaoxuan Chen; Qian Huang; Yuexin Chen; Zhiyu Guan; Yongxing Zhang
Journal:  Exp Ther Med       Date:  2015-07-15       Impact factor: 2.447

Review 4.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

Review 5.  B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies.

Authors:  José P Vaqué; Nerea Martínez; Ana Batlle-López; Cristina Pérez; Santiago Montes-Moreno; Margarita Sánchez-Beato; Miguel A Piris
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

6.  Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma.

Authors:  Teresa Amato; Francesco Abate; Pierpaolo Piccaluga; Michele Iacono; Chiara Fallerini; Alessandra Renieri; Giulia De Falco; Maria Raffaella Ambrosio; Vaselious Mourmouras; Martin Ogwang; Valeria Calbi; Roul Rabadan; Michael Hummel; Stefano Pileri; Lorenzo Leoncini; Cristiana Bellan
Journal:  Am J Clin Pathol       Date:  2016-01       Impact factor: 2.493

7.  Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.

Authors:  Fan Ni; Xianbo Huang; Zhenzhen Chen; Wenbin Qian; Xiangmin Tong
Journal:  Sci Rep       Date:  2018-02-20       Impact factor: 4.379

8.  Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.

Authors:  Aarthi Kannan; Zhenyu Lin; Qiang Shao; Stephanie Zhao; Bin Fang; Mauricio A Moreno; Emre Vural; Brendan C Stack; James Y Suen; Krishnaswamy Kannan; Ling Gao
Journal:  Oncotarget       Date:  2016-02-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.